Literature DB >> 9288572

Melatonin in relation to cellular antioxidative defense mechanisms.

R J Reiter1, R C Carneiro, C S Oh.   

Abstract

Melatonin's actions in organisms are more widespread than originally envisaged. Over three decades ago, the changing pattern of nocturnal melatonin production was found to be the signal for the annual cycle of reproduction in photoperiodic species. Since then, melatonin's actions also have been linked to circadian rhythms, immune function, sleep, retinal physiology and endocrine functions in general. In recent years, however, the sphere of influence of melatonin was further expanded when the indole was found to be an effective free radical scavenger and antioxidant. Free radicals are toxic molecules, many being derived from oxygen, which are persistently produced and incessantly attack and damage molecules within cells; most frequently this damage is measured as peroxidized lipid products, carbonyl proteins, and DNA breakage or fragmentation. Collectively, the process of free radical damage to molecules is referred to as oxidative stress. Melatonin reduces oxidative stress by several means. Thus, the indole is an effective scavenger of both the highly toxic hydroxyl radical, produced by the 3 electron reduction of oxygen, and the peroxyl radical, which is generated during the oxidation of unsaturated lipids and which is sufficiently toxic to propagate lipid peroxidation. Additionally, melatonin may stimulate some important antioxidative enzymes, i.e., superoxide dismutase, glutathione peroxidase and glutathione reductase. In in vivo tests, melatonin in pharmacological doses has been found effective in reducing macromolecular damage that is a consequence of a variety of toxic agents, xenobiotics and experimental paradigms which induce free radical generation. In these studies, melatonin was found to significantly inhibit oxidative damage that is a consequence of paraquat toxicity, potassium cyanide administration, lipopolysaccharide treatment, kainic acid injection, carcinogen administration, carbon tetrachloride poisoning, etc., as well as reducing the oxidation of macromolecules that occurs during strenuous exercise or ischemia-reperfusion. In experimental models which are used to study neurodegenerative changes associated with Alzheimer's and Parkinson disease, melatonin was found to be effective in reducing neuronal damage. Its lack of toxicity and the ease with which melatonin crosses morphophysiological barriers and enters subcellular compartments are essential features of this antioxidant. Thus far, most frequently pharmacological levels of melatonin have been used to combat oxygen toxicity. The role of physiological levels of melatonin, which are known to decrease with age, is being investigated as to their importance in the total antioxidative defense capacity of the organism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288572     DOI: 10.1055/s-2007-979057

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  26 in total

1.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

2.  Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species.

Authors:  Miguel A Ortiz-Ortiz; José M Morán; Jose M Bravosanpedro; Rosa A González-Polo; Mireia Niso-Santano; Vellareddy Anantharam; Anumantha G Kanthasamy; Germán Soler; José M Fuentes
Journal:  Neurotoxicology       Date:  2009-08-04       Impact factor: 4.294

Review 3.  Melatonin and nitric oxide.

Authors:  S Aydogan; M Betul Yerer; A Goktas
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

4.  Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury.

Authors:  Matthew L Kelso; Nicole N Scheff; Stephen W Scheff; James R Pauly
Journal:  Neurosci Lett       Date:  2010-11-05       Impact factor: 3.046

Review 5.  Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?

Authors:  Naveen Kumar Singhal; Garima Srivastava; Sonal Agrawal; Swatantra Kumar Jain; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2011-12-24       Impact factor: 5.590

Review 6.  Antioxidant therapies in traumatic brain and spinal cord injury.

Authors:  Mona Bains; Edward D Hall
Journal:  Biochim Biophys Acta       Date:  2011-11-04

7.  Protective effect of melatonin on naphthalene-induced oxidative stress and DNA damage in cultured macrophage J774A.1 cells.

Authors:  M Bagchi; J Balmoori; X Ye; D Bagchi; S D Ray; S J Stohs
Journal:  Mol Cell Biochem       Date:  2001-05       Impact factor: 3.396

Review 8.  Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas.

Authors:  Russel J Reiter; Sergio Rosales-Corral; Dun Xian Tan; Mei Jie Jou; Annia Galano; Bing Xu
Journal:  Cell Mol Life Sci       Date:  2017-09-01       Impact factor: 9.261

Review 9.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

10.  Inhibition of creatine kinase activity by lysine in rat cerebral cortex.

Authors:  Anelise Miotti Tonin; Gustavo Costa Ferreira; Patrícia Fernanda Schuck; Carolina Maso Viegas; Angela Zanatta; Guilhian Leipnitz; Bianca Seminotti; Clóvis Milton Duvall Wannmacher; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-04-16       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.